Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01604408
Registration number
NCT01604408
Ethics application status
Date submitted
21/05/2012
Date registered
23/05/2012
Date last updated
25/04/2018
Titles & IDs
Public title
A Study in Older Participants Who Have Fallen and Have Muscle Weakness
Query!
Scientific title
A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Who Have Fallen Recently and Have Muscle Weakness
Query!
Secondary ID [1]
0
0
I1Q-MC-JDDJ
Query!
Secondary ID [2]
0
0
14499
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Muscle Weakness
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - LY2495655
Treatment: Drugs - Placebo
Experimental: LY2495655 - Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.
Placebo Comparator: Placebo - Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.
Other interventions: LY2495655
Administered SC
Treatment: Drugs: Placebo
Administered SC
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline to 24 Week Endpoint in Appendicular Lean Body Mass (aLBM)
Query!
Assessment method [1]
0
0
Change from baseline to 24-week endpoint in aLBM, as measured by dual energy x-ray absorptiometry (DEXA), is presented. Least squares (LS) means were calculated using a mixed model repeated measures (MMRM) with treatment, visit, and treatment-by-visit interaction as fixed effects and baseline aLBM as covariate.
Query!
Timepoint [1]
0
0
Baseline to 24 weeks
Query!
Secondary outcome [1]
0
0
Change From Baseline in Stair Climbing (StC) Time
Query!
Assessment method [1]
0
0
Change from baseline to the 24-week endpoint in StC time is presented. StC time was assessed by measuring the fastest time achieved to climb 4 steps on a 4-step staircase (the test was performed 2 times). LS means were calculated using a MMRM with treatment, visit, and treatment-by-visit interaction as fixed effects and baseline StC score as covariate.
Query!
Timepoint [1]
0
0
Baseline to 24 weeks
Query!
Secondary outcome [2]
0
0
Change From Baseline in Repeated Chair Stands (RCS) Time
Query!
Assessment method [2]
0
0
Change from baseline to 24-week endpoint in RCS time is presented. In the RCS test, participants were asked to rise from a chair 5 times as fast as possible with their arms folded on their chest. Performance was measured in seconds, as the time from the initial seated position to the final standing position. LS means were calculated using an MMRM with treatment, visit, and treatment-by-visit interaction as fixed effects and baseline RCS time as covariate.
Query!
Timepoint [2]
0
0
Baseline to 24 weeks
Query!
Secondary outcome [3]
0
0
Change From Baseline in Usual Gait Speed (uGS) at 4 Meters
Query!
Assessment method [3]
0
0
Change from baseline to the 24-week endpoint in uGS is presented. Two attempts to walk a 4-meter distance were made. LS means were calculated using a MMRM with treatment, visit, and treatment-by-visit interaction as fixed effects and baseline uGS as covariate.
Query!
Timepoint [3]
0
0
Baseline to 24 weeks
Query!
Eligibility
Key inclusion criteria
- Sustained at least 1 fall within 1 calendar year before study screening.
- Requires =12 seconds to perform a repeated chair stands test or is unable to complete
this test at screening.
- Hand grip strength is =37 kilograms (kg) for men (81.4 pounds) or =21 kg for women
(46.2 pounds) at screening.
- Can stand up from a chair and walk =10 meters without human assistance (gait aids such
as cane[s], crutches, or walkers are acceptable) at screening.
- Able to climb at least 1 step on a staircase without human assistance according to the
participant at screening (using handrails is allowed).
- Have screening clinical laboratory test results within normal reference range for the
population, or have results with acceptable deviations that are judged to be not
clinically significant by the investigator.
Query!
Minimum age
75
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Major lower limb pain or neurologic impairment or vestibular vertigo or visual
impairment that could severely confound measures of physical performance.
- Recent lower limb fracture and/or major lower limb surgery.
- Planned major surgical procedure within 6 months following study drug dosing.
- Have had a lower extremity amputation of the foot, leg, and/or thigh.
- Have a body mass index (BMI) =35 kilogram per meter squared (kg/m2).
- Severe vitamin D deficiency.
- Underlying muscle disease other than age-associated muscle waste or disuse atrophy.
- Current use or previous use of any drugs known to influence muscle mass or
performance.
- Have had a recent neurologic injury (<6 months before study drug dosing), such as
stroke or spinal cord injury.
- History of a malignant neoplasm in the 18 months before first study drug dosing.
- Have a history or presence of unstable cardiovascular or pulmonary comorbidities.
- Have a positive fecal occult blood (FOB) test at screening, or the participant cannot
provide a stool sample for FOB testing before first study drug dosing.
- Have either severe ongoing liver disease or aspartate aminotransferase (AST) or
alanine aminotransferase (ALT) >2 times upper limit of normal (ULN), alkaline
phosphatase (ALP) >1.5 times ULN, or total bilirubin >1.5 times ULN at screening.
- Have an estimated creatinine clearance <20 milliliters per minute (mL/minute).
- Have a history of severe allergic reaction to a monoclonal antibody.
- Are males with a female partner of childbearing potential who do not agree to use
contraception during the treatment period of the study and up to 15 weeks after the
last dose of investigational product (study drug).
- Have known allergies to LY2495655, its constituents, or related compounds.
- Have severe active psychiatric disease or cognitive impairment as assessed by the
Mini-Mental State Examination (MMSE) score <22 (for a participant who went to school
up to age 15 years or less) or <24 (for a participant who went to school up to at
least age 16), making the participant unlikely to understand the informed consent form
or comply with protocol procedures.
- Exhibit excessive consumption of alcohol or abuse of drugs.
- Have uncontrolled diabetes mellitus.
- Have had ocular trauma, ophthalmologic surgery, or eye laser treatment within 6 months
before study drug dosing.
- Have hyponatremia (serum sodium levels <135 millimoles/liter ([mmol/L]) at screening
unless a retest shows normonatremia before study drug dosing.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/05/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/12/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
201
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Hornsby
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Kingswood
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Daw Park
Query!
Recruitment postcode(s) [1]
0
0
2077 - Hornsby
Query!
Recruitment postcode(s) [2]
0
0
2747 - Kingswood
Query!
Recruitment postcode(s) [3]
0
0
5041 - Daw Park
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Colorado
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Georgia
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Massachusetts
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Missouri
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
North Carolina
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Texas
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Wisconsin
Query!
Country [8]
0
0
Argentina
Query!
State/province [8]
0
0
Buenos Aires
Query!
Country [9]
0
0
Argentina
Query!
State/province [9]
0
0
Caba
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Montpellier
Query!
Country [11]
0
0
France
Query!
State/province [11]
0
0
Paris
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Pessac
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Pierre Benite
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Toulouse
Query!
Country [15]
0
0
Germany
Query!
State/province [15]
0
0
Köln
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Stuttgart
Query!
Country [17]
0
0
Sweden
Query!
State/province [17]
0
0
Huddinge
Query!
Country [18]
0
0
Sweden
Query!
State/province [18]
0
0
Mölndal
Query!
Country [19]
0
0
Sweden
Query!
State/province [19]
0
0
Uppsala
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
LY2495655 is an investigational drug being tested for muscle wasting.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01604408
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01604408
Download to PDF